Pharmicell Eyes US After Promising Cirrhosis Cell Therapy Results
Executive Summary
South Korea's Pharmicell is taking steady steps towards commercializing a stem cell therapy for alcoholic liver cirrhosis, an area with outstanding needs, following a successful Phase II domestic trial that lays the ground for a Phase III program and the start of US clinical development.